Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POOL: Verteporfin for Occult CNV in AMD
NCT00135837Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2003
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of verteporfin in age-related macular degeneration (AMD), sponsored by Novartis. Primary endpoint: Visual Acuity Measurements at 12 months. Started Jun 2003; status: completed.
02
Drugs
verteporfin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00135837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135837.